How to use the speech recognition tool?

NCT03328130

Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression

Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression

Type: Interventional



Status of the trial: Active, Recruiting

Orphan Drug Recognition: Yes

Inclusion

  • Opening Date: 2017-11-06
  • Closing Date: 2020-06-30

Criteria

Inclusion: age ≥ 18 years ; clinical and molecular diagnosis of retinitis pigmentosa caused by defect in PDE6B gene without other syndromic manifestations

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Principal investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: